MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-08-2026
ANI Pharmaceuticals DPO Ratio 2011-2026 | ANIP
Annual DPO Ratio ANI Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.9 | 60.1 | 66.3 | 68.7 | 62.1 | 54.2 | 84.4 | 44.4 | 16.8 | 25.4 | 59.4 | 84.4 | 52.3 | - | 23 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23 K | 16.8 | 1.7 K |
Quarterly DPO Ratio ANI Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68 | 60.8 | 65.8 | 71.2 | 79.3 | 38.5 | 31.6 | 59.4 | 66 | 75 | - | 64.7 | 64.2 | 59.9 | - | 45.8 | 54.7 | 57.1 | - | 51.1 | 49.6 | 54.1 | - | 88.8 | 85.3 | 72.8 | - | 52 | 48.9 | 27.6 | - | 15.7 | 15.7 | 19.5 | - | 18.6 | 26.2 | 73 | - | 57.8 | 60 | 78.3 | - | 79.1 | 114 | 71 | - | 48.1 | 60.1 | 64.9 | - | 78.3 | 67.2 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114 | 15.7 | 58.1 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Coherus BioSciences
CHRS
|
507 | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |  Britain |
 |
Eton Pharmaceuticals
ETON
|
74.3 | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Exelixis
EXEL
|
148 | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
400 | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Gilead Sciences
GILD
|
45.3 | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.12 | - | $ 649 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |